newsfilter
← Latest News
GlobeNewswire·

Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025

  • Aligos Therapeutics, Inc. (NASDAQ: ALGS) will report its third quarter 2025 financial results on Thursday, November 6, 2025, before the U.S. financial markets open.
  • The company is a clinical stage biopharmaceutical firm focused on developing therapies for liver and viral diseases, including chronic hepatitis B, obesity, MASH, and coronaviruses.
  • Aligos plans to update investors via its website, LinkedIn, or X for further information.
  • The press release includes forward-looking statements subject to risks related to drug development, clinical trials, and regulatory approval processes.
  • Detailed risk factors are described in Aligos' Form 10-Q filed with the SEC on August 6, 2025, with no obligation to update statements unless required by law.
  • Investor relations inquiries can be directed to Vice President Jordyn Tarazi at (650) 910-0427 or jtarazi@Aligos.com.